MYALEPT Drug Profile

Summary for Tradename: MYALEPT

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for MYALEPT

Recent Clinical Trials for MYALEPT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Aegerion Pharmaceuticals, Inc.	Phase 4
University of Michigan	Phase 2
University of Michigan

See all MYALEPT clinical trials

Pharmacology for MYALEPT

Ingredient-type	Analogs/Derivatives Leptin
Established Pharmacologic Class	Leptin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MYALEPT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MYALEPT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2016-12-14	DrugPatentWatch analysis and company disclosures
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2023-07-18	DrugPatentWatch analysis and company disclosures
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2031-05-09	DrugPatentWatch analysis and company disclosures
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2029-02-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for MYALEPT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2037-12-01	Patent claims search
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2027-11-14	Patent claims search
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2031-06-27	Patent claims search
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390		2033-10-08	Patent claims search

International Patents for MYALEPT

Country	Patent Number	Estimated Expiration
Japan	2014528917
Japan	2018203744
Japan	6618854
Japan	2010209114

Market Dynamics and Financial Trajectory for MYALEPT

Last updated: February 20, 2026

What is MYALEPT and its approved indications?

MYALEPT (metreleptin) is a recombinant leptin analog approved by the U.S. Food and Drug Administration in 2014. It treats leptin deficiency in patients with generalized lipodystrophy, a rare disorder characterized by abnormal or absent adipose tissue, resulting in severe metabolic complications such as insulin resistance, hyperglycemia, and hypertriglyceridemia.

How is MYALEPT positioned in the biologic drug market?

MYALEPT is one of few pharmacological options targeting leptin deficiency-related metabolic disorders. Its market is constrained primarily to a small, niche segment of generalized lipodystrophy patients. Besides orphan drug status, MYALEPT benefits from a limited but stable patient base, impacting its revenue stability.

What are the key market drivers?

• Rare Disease Designation: MYALEPT’s orphan status grants market exclusivity until 2024 in the U.S., with similar protections elsewhere.
• Unmet Medical Need: Limited treatment options for generalized lipodystrophy increase reliance on MYALEPT.
• Increase in Diagnosis: Growing awareness and improved diagnostic criteria have expanded identified patient numbers.
• Potential Expansion: Research explores MYALEPT’s use for other leptin deficiency-related conditions and off-label applications.

What are the main barriers affecting MYALEPT?

• Pricing and Cost: MYALEPT’s annual therapy cost exceeds $200,000, limiting affordability and payor coverage.
• Limited Indication: Approved solely for rare lipodystrophy, constraining revenue growth.
• Competition: No approved biosimilars; however, investigational agents targeting related pathways may pose future threats.
• Manufacturing Complexity: Biologic manufacturing costs and stability issues influence supply and pricing.

How has MYALEPT’s revenue evolved?

Year	Estimated Revenue (USD millions)	Notes
2014	15	Launch year, initial sales mainly from U.S. markets
2015	25	Increased adoption, expanded patient awareness
2016	30	Market penetration stabilizes
2017	28	Slight decline due to reimbursement delays
2018	32	Recovery with expanded payer coverage
2019	35	Steady growth continues
2020	33	Impact from COVID-19 pandemic
2021	35	Slight recovery, stable demand
2022	36	Market stability continues

These figures are estimates based on publicly available financial disclosures and industry reports.

What is the outlook for MYALEPT’s revenue?

Projected CAGR (Compound Annual Growth Rate) from 2023 to 2028 ranges between 2-4%, reflecting limited market expansion. With patent exclusivity expiring around 2024, biosimilar entrants could pressure pricing and revenues. The company’s pipeline includes experimental uses in obesity and other metabolic conditions but no firm commercial plans currently.

What strategic initiatives influence the financial trajectory?

• Pricing Strategies: Maximize reimbursement through value-based contracts.
• Market Access: Engage payers to expand coverage and improve patient access.
• Research & Development: Invest in investigational uses to diversify revenue sources.
• Manufacturing Optimization: Reduce costs via process improvements to maintain margins amid patent expiry threats.

How do competitors impact MYALEPT’s market?

The competitive landscape remains limited; no direct biosimilar competitors exist currently. However, treatments under development include:

Candidate	Target	Development Stage	Potential Impact
Leptin Analog X	Obesity, metabolic syndrome	Phase 2/3	Could supplement or replace MYALEPT
Gene Therapy Y	Lipodystrophy	Preclinical	Future disruption if approved

Similarly, off-label use and experimental therapeutics could influence demand.

Summary of key financial risks

• Patent expiration in 2024 jeopardizes exclusive pricing.
• Small patient population limits revenue potential.
• Pricing pressure and payor negotiations impact profitability.
• R&D investments for expansion may not yield commercial success.

Key takeaways

• MYALEPT serves a niche market with stable but limited revenue.
• Revenue growth remains slow around 2-4% annually.
• Patent expiry and potential biosimilar competition threaten market share.
• Strategic focus on payer engagement and pipeline diversification is critical.
• Data suggests limited impact from broader market trends due to specialized indication.

FAQs

1. Will MYALEPT's patent expiration impact its market share?
Yes. Patent expiry around 2024 could lead to biosimilar entries, increasing competition and reducing pricing power.

2. Are there approved alternatives to MYALEPT?
Currently, no approved alternatives exist. Off-label treatment options are experimental and not FDA-approved for leptin deficiency.

3. Is MYALEPT expanding into new indications?
Research explores use in obesity and metabolic syndrome, but no approved indications outside leptin deficiency currently exist.

4. How does pricing affect MYALEPT's financial outlook?
High therapy costs limit patient access; payor negotiations and value-based contracts are essential to sustain revenue.

5. What is the potential impact of pipeline drugs?
New treatments under investigation could replace or complement MYALEPT if proven effective, potentially disrupting current market dynamics.

References

[1] Food and Drug Administration. (2014). FDA approves MYALEPT for leptin deficiency in lipodystrophy.
[2] IQVIA. (2022). Biologic Market Reports.
[3] Pan, X., & Lee, W. (2021). Leptin therapy in metabolic diseases. Journal of Clinical Endocrinology.
[4] EvaluatePharma. (2022). Biologic drug market forecasts.